Bavarian Nordic Rises As It Meets Demand For Monkeypox Vaccine
Shares Up 42% Following Unexplained Outbreaks
The Danish company has the world’s only licensed monkeypox vaccine and is now fielding enquiries from concerned governments from around the world.
You may also be interested in...
Bavarian Nordic Deal Opens Up Potential China Market For RSV Vaccine
As three big players get set to reveal pivotal data for adult RSV vaccines, Bavarian Nordic seals a deal for its candidate that could still claim a sizeable niche if a late-stage trial delivers.
Vertex’s Sickle Cell Treatment Gets December Decision Date, On Track To Be First CRISPR Therapy
Vertex now looks likely to gain US approval for the first ever CRISPR gene edited therapy by the end of the year, but could face immediate competition from Bluebird Bio.
AstraZeneca To Partner With Quell In Buzzing Treg Field
AstraZeneca has paid $85m upfront to develop Tregs against two autoimmune conditions, type 1 diabetes and inflammatory bowel disease